{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:28:08Z","timestamp":1760909288469,"version":"3.41.2"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>An unmet medical need exists for many oncology patients who cannot be treated satisfactorily by available therapeutic options. Early access provision (EAP) is endorsed by competent authorities to improve patient access to innovative medicinal products (InMPs). This paper determined awareness and understanding among practicing physicians of integrated EAP protocols, and of the procedures involved in EAP applications for oncology trials prior to marketing authorization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An on-line, fully anonymous survey reaching out to more than 3,258 physicians (including practicing oncologists) was initiated between November 2020 - January 2021. Participants were questioned about their knowledge and understanding of EAP and the decision processes involved, level of experience, interest for further educational activities and opportunities to improve the process, both in general and specifically during the COVID-19 pandemic. The frequency of EAP protocols for oncology InMPs was identified by a search of <jats:uri>ClinicalTrials.gov<\/jats:uri> and EU Clinical Trials registers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Survey results (75% oncologists) indicated 75% of respondents were \u2018very comfortable\u2019 or \u2018comfortable\u2019 with using EAP for their patients, but only 54.5% correctly answered the specific knowledge-based question related to the EAP definition. For 56% of respondents, experience with EAP in daily practice was very limited. Two-thirds indicated an average or lower level of understanding about the application process and regulatory requirements involved (65.2% and 66.0%, respectively). Knowledge on data collection and serious adverse event reporting under EAP was lower at 57.8% and 50.5% of respondents, respectively. Awareness of physician responsibilities was high in 59.7% of respondents, but fewer understood roles and responsibilities of manufacturing companies (31.2%). Most indicated they would consider clinical efficacy and safety data from comparative phase III randomized controlled trials as of high importance to support their decision to apply for EAP (93.4% and 86.8%, respectively). During the COVID-19 pandemic, the majority of respondents highlighted the need to improve and adapt EAP with regard to the application process and documentation (83.8%), InMP supply and logistics (88.4), and safety reporting process (78.0%). Of identified oncology trials with a ClinicalTrials.gov protocol, only 149 (0.4%) included EAP, and 23 used the data to receive a marketing authorization during the period Jan 2015 to December 2020. Of oncology trials with a EudraCT protocol, only 21 (0.23%) included EAP, of which 6 were used to receive a conditional or full marketing authorisation over the same period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Use of EAP in daily practice remains limited. Challenges posed by the EAP process, together with a lack of education on this topic, might contribute to its under-utilization and influence access of oncology patients to care. Continuous educational efforts from different stakeholders are required to better inform and support practicing oncologists during the EAP application process and regulatory framework follow up. Education should also be provided on EAP roles and responsibilities, monitoring, and potential adaptations when faced with specific challenges, such as the current COVID-19 pandemic.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.714516","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T08:54:32Z","timestamp":1666774472000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Early access provision: Awareness, educational needs and opportunities to improve oncology patients\u2019 access to care"],"prefix":"10.3389","volume":"12","author":[{"given":"Andriy","family":"Krendyukov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Singhvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yianick","family":"Green-Morrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Zabransky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-020-00328-x","article-title":"RARECAREnet working group. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study","volume":"18","author":"Gatta","year":"2017","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01604","article-title":"The burden of rare cancers in the united states","volume":"67","author":"DeSantis","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2168479016656030","article-title":"RARECARENet working group. Epidemiology of rare cancers and inequalities in oncologic outcomes","volume":"45","author":"Gatta","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e18585","article-title":"Critical factors shaping strategy development of an innovative medicine in oncology","volume":"34","author":"Krendyukov","year":"2020","journal-title":"Pharmaceut Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01604","article-title":"Early access provision for innovative medicinal products in oncology: Challenges and opportunities","volume":"10","author":"Krendyukov","year":"2020","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03420","article-title":"FDA Breakthrough therapy designation for oncology products: the CBER experience","volume":"36","author":"Singh","year":"2018","journal-title":"J Clin Oncol"},{"key":"B8","unstructured":"Launch of PRIME\u2013paving the way for promising medicines for patients2016"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMhle1409465","article-title":"Clinical cancer advances 2021: ASCO's report on progress against cancer","volume":"39","author":"Smith","year":"2021","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13063-015-1108-0","article-title":"Patient recruitment driving length and cost of oncology clinical trials","volume":"5","author":"Bianchi","year":"2013","journal-title":"Clin Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2016.01054","article-title":"Practical, legal, and ethical issues in expanded access to investigational drugs","volume":"372","author":"Darrow","year":"2015","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13063-015-1108-0","article-title":"Expanded access programme: Looking for a common definition","volume":"17","author":"Ludicello","year":"2016","journal-title":"Trials."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2016.01054","article-title":"An overview of compassionate use programs in the European union member states","volume":"5","author":"Balasubramanian","year":"2016","journal-title":"Intract Rare Dis Res"},{"key":"B14","unstructured":""},{"key":"B15","unstructured":"Special access program for drugs: guidance document for industry and practitioners2020"},{"key":"B16","unstructured":"Therapeutic goods administration. special access scheme"},{"key":"B17","unstructured":"Guide to drug approval system in Korea2017"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/2168479016656030","article-title":"Expanded access of investigational drugs: The experience of the center of drug evaluation and research over a 10-year period","volume":"50","author":"Jarow","year":"2016","journal-title":"Ther Innov Regul Sci"},{"key":"B19","unstructured":"Silver Spring,MD: U.SFDA Center for Drug Evaluation and Research (CDERExpanded access to investigational drugs for treatment use\u2013questions answers; guidance for industry2017"},{"key":"B20","unstructured":""},{"key":"B21","doi-asserted-by":"publisher","first-page":"abstr.e19070","DOI":"10.1007\/s40487-018-0061-y","article-title":"Explorative analysis of expanded access for intermediate-size and larger patient populations: Opportunities for access provision to care","volume":"38","author":"Krendyukov","year":"2020","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/bjh.16462","article-title":"Osimertinib for previously treated patients with advanced EGFR T790M mutation-positive NSCLC: Tolerability and diagnostic methods from an expanded access program","volume":"6","author":"Santos","year":"2018","journal-title":"Oncol Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/jcph.960","article-title":"Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts","volume":"189","author":"Al-Ali","year":"2020","journal-title":"Br J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/2168479017707800","article-title":"How often are drugs made available under the food and drug administration\u2019s expanded access process approved","volume":"57","author":"McKee","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0081-7","article-title":"Impact of expanded access on FDA regulatory action and product labelling","volume":"51","author":"Jarow","year":"2017","journal-title":"Ther Innov Regul Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0081-7","article-title":"What compassionate use means for gene therapies","volume":"37","author":"Chapman","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B27","article-title":"Compassionate use programme of irinotecan in colorectal cancer patients in the Netherlands","volume":"61","author":"Ten Bokkel Huinink","year":"2003","journal-title":"Neth J Med"},{"key":"B28","unstructured":"FDA Approves new treatment for certain digestive tract cancers2018"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3791","article-title":"Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology","volume":"10","author":"Shulman","year":"2021","journal-title":"Cancer Med"},{"key":"B30","unstructured":"Leveraging real-world treatment experience from expanded access protocols2018"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical benefit scale version 1","volume":"28","author":"Cherny","year":"2017","journal-title":"1. Ann Oncol"},{"key":"B32","unstructured":"2016"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of clinical oncology statement: A conceptual framework to assess the value of cancer treatment options","volume":"33","author":"Schnipper","year":"2015","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"djaa137","DOI":"10.1007\/s11673-021-10090-7","article-title":"\"I think it's been met with a shrug:\" oncologists' views toward and experiences with right-to-Try","volume":"3","author":"Smith","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s11673-021-10090-7","article-title":"The role of physicians in expanded access to investigational drugs: A mixed-methods study of physicians' views and experiences in the Netherlands","volume":"18","author":"Bunnik","year":"2021","journal-title":"J Bioeth Inq"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_278995","article-title":"Physician perspectives on compassionate use in pediatric oncology","volume":"66","author":"Moerdler","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03007995.2021.1941827","article-title":"Before it's too late: Multistakeholder perspectives on compassionate access to investigational drugs for pediatric patients with cancer","volume":"40","author":"Gerasimov","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1941827","article-title":"Educational needs, perception, and perspectives of oncologists regarding compassionate use programs in Asia","volume":"37","author":"Singh","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"B39","unstructured":"WashingtonReagan-Udall Foundation"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2018.12.002","article-title":"Participants of giens XXXIV round table \u201cOrganisational and regulatory aspects\u201d; with collaboration. Early access to health products in France: Major advances of the French \"Conseil strat\u00e9gique des industries de sant\u00e9\" (CSIS) to be implemented (modalities, regulations, funding)","volume":"74","author":"Albin","year":"2019","journal-title":"Therapie"},{"volume-title":"Cohort temporary authorisation for use in France: French experience of early-entry program 2014-2018. ISPOR Europe 2018","year":"2018","author":"Weber","key":"B41"},{"key":"B42","unstructured":"CossetD\n            LegrossC\n            HaugenJ\n            MeddebL\n          ATU in France: the case for early consideration in local and European P&MA strategy2020"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.714516\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T08:54:40Z","timestamp":1666774480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.714516\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":42,"alternative-id":["10.3389\/fonc.2022.714516"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.714516","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"article-number":"714516"}}